Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | EPOR | P19235 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465552 | 0.90 | CA12 (0.40) | EPHX2EPORSMN1; SMN2GLP1RMEN1 | |
| SCHEMBL20353234 | 0.88 | EPHX2 (0.43) | EPHX2GLP1RPRMT1KDM4E | |
| SCHEMBL22271542 | 0.88 | EPHX2 (0.47) | TSHRLMNAEPHX2GLP1RPRMT1 | |
| SCHEMBL20353221 | 0.88 | EPHX2 (0.43) | EPHX2GLP1RPRMT1KDM4E | |
| SCHEMBL15773390 | 0.88 | EPHX2 (0.47) | TSHRLMNAEPHX2GLP1RPRMT1 | |
| SCHEMBL24982646 | 0.88 | EPHX2 (0.43) | EPHX2GLP1RPRMT1KDM4E | |
| SCHEMBL20353132 | 0.88 | EPHX2 (0.43) | EPHX2GLP1RPRMT1KDM4E | |
| SCHEMBL20353219 | 0.88 | EPHX2 (0.43) | EPHX2GLP1RPRMT1KDM4E | |
| SCHEMBL20353151 | 0.88 | EPHX2 (0.43) | EPHX2GLP1RPRMT1KDM4E | |
| SCHEMBL30601897 | 0.88 | EPHX2 (0.43) | EPHX2GLP1RPRMT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2023-11-30 | — | — | US | claimed |
| CN-105744935-B | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | NOD2, TLR7, TLR9 | TSHR 2051/4885LMNA 3389/4885EPHX2 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.